ClinicalTrials.gg
CompletedNCT06447688Updated Oct 10, 2025Results posted

The Role of Verapamil in Radial Artery Spasm

A Phase 4 interventional study of Verapamil in Radial Artery Spasm, sponsored by Mersin Medicalpark Hastanesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Mersin Medicalpark Hastanesi · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Coronary angiography (CAG) is an invasive imaging method performed to determine the degree of coronary artery disease. Radial artery spasm (RAS) is one of the most common complications during coronary angiography performed via the transradial approach, causing patient discomfort or sometimes interrupting the procedure. There are many studies on RAS, and various pharmacoagents administered intravenously (intraarterial) to prevent RAS have been described. However, there is limited data in the literature regarding oral pharmacoagents that will prevent this complication. In our study, the preventive effect of Verapamil, given orally 2 hours before coronary angiography, on radial artery spasm will be investigated.

Read the detailed description

Transradial access (TRA) has emerged as the preferred modality for vascular access in coronary interventions worldwide, prompting growing interest in its potential applications across other interventional specialties, especially in neurovascular procedures. Radial artery spasm (RAS) remains the most common complication of TRA, often causing procedural difficulties, patient discomfort, and an increased risk of access site crossover. The incidence of radial artery spasm reported in the literature varies widely, with estimates ranging from 4% to over 51.3%, influenced by factors such as definitions, patient selection, and the operator's experience.

After puncturing the radial artery (Puncture-induced RAS) and inserting the sheath-but before administering intra-arterial spasmolytics-local discomfort and pain may trigger a sympathetic vasoconstrictive response, potentially leading to the onset of RAS.

A previous study has stated that preventing RAS is more effective than treating it after it has been established. In this context, we will conduct a randomized controlled trial to evaluate the efficacy of 120 mg of oral verapamil administered two hours before radial artery puncture in reducing the incidence of radial artery spasm (RAS)

02

Conditions studied

  • Radial Artery Spasm

Browse trials for

Keywords

  • radial artery spasm, verapamil, transradial access
03

In context

Spasm

123 studies on the registry are indexed under Spasm; 7 are open to participants now.

This study's enrollment of 150 is above the median of 80 across 104 interventional studies indexed under Spasm.

Browse Spasm studies →

Lead sponsor

Mersin Medicalpark Hastanesi is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who undergo daily coronary angiography
  • Whose Allen test is normal.
  • Must be able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • Allen test results are distorted,
  • No pulse in the radial artery,
  • Patients who have previously undergone radial angiography and whose hemodynamics are compromised will be excluded from the study.
  • Patients with known to verapamil (significant aortic stenosis, heart rate \<50/min, high-grade atrioventricular block, myocardial infarction) complicated with cardiogenic shock, or \<35%).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    No other vasodilating drug such as nitrate will be given intravenously

    Drug: Verapamil

  • Active comparator
    Verapamil

    Verapamil will be given orally at least 2 hours before angiography

    Drug: Verapamil

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinical Radial Artery Spasm (RAS)

    Clinical RAS defined as presence of at least 2 of the following: (1) forearm pain ≥ 4/10, (2) pain during catheter manipulation, (3) catheter movement restriction, (4) pain during sheath removal, (5) difficulty in sheath removal.

    Time frame: During the coronary angiography procedure (up to 2 hours from sheath insertion)

  2. Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)

    Radial artery spasm (RAS) was defined as luminal narrowing of ≥50% as measured by ultrasonography at the access site.

    Time frame: During the procedure, immediately after catheterization (within 2 hours)

Secondary outcomes

  1. Number of Participants With Procedural Success

    Procedure success was defined as completing coronary angiography or PCI using the initial radial artery approach without requiring a switch to an alternative access site.

    Time frame: During the procedure (from sheath insertion to procedure completion)

  2. Mean Volume of Contrast Media Used (mL) (mL)

    The volume of contrast media (in ml) used was recorded

    Time frame: During the procedure (from sheath insertion to procedure completion)

  3. Mean of the Dose Area Product (DAP)

    The parameters collected for radiation exposure included the DAP

    Time frame: During the procedure (from sheath insertion to procedure completion)

  4. Mean of the Fluoroscopy Time

    The parameters collected for radiation exposure included the fluoroscopy time (in minutes)

    Time frame: During the procedure (from sheath insertion to procedure completion)

07

Results

Posted Oct 10, 2025

Participant flow

All consecutive patients undergoing transradial coronary angiography between June-November 2024 at Medicalpark Hospital (Mersin, Turkey) were included. Exclusion criteria were abnormal Allen test, absent radial pulse, prior radial access, hemodynamic instability, or contraindications to verapamil (e.g., severe AS, HR \<50, high-grade AV block, cardiogenic shock, EF \<35%).

Participant flow — Overall Study
MilestonePlaceboVerapamil
Started7575
Completed7575
Not completed00

Outcome measures

PrimaryNumber of Participants With Clinical Radial Artery Spasm (RAS)

Clinical RAS defined as presence of at least 2 of the following: (1) forearm pain ≥ 4/10, (2) pain during catheter manipulation, (3) catheter movement restriction, (4) pain during sheath removal, (5) difficulty in sheath removal.

Time frame:
During the coronary angiography procedure (up to 2 hours from sheath insertion)
Reported as:
Number · participants
Number of Participants With Clinical Radial Artery Spasm (RAS)
participantsPlaceboVerapamil
Number of Participants With Clinical Radial Artery Spasm (RAS)233
PrimaryNumber of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)

Radial artery spasm (RAS) was defined as luminal narrowing of ≥50% as measured by ultrasonography at the access site.

Time frame:
During the procedure, immediately after catheterization (within 2 hours)
Reported as:
Number · participants
Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)
participantsPlaceboVerapamil
Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)368
SecondaryNumber of Participants With Procedural Success

Procedure success was defined as completing coronary angiography or PCI using the initial radial artery approach without requiring a switch to an alternative access site.

Time frame:
During the procedure (from sheath insertion to procedure completion)
Reported as:
Number · participants
Number of Participants With Procedural Success
participantsPlaceboVerapamil
Number of Participants With Procedural Success7575
SecondaryMean Volume of Contrast Media Used (mL) (mL)

The volume of contrast media (in ml) used was recorded

Time frame:
During the procedure (from sheath insertion to procedure completion)
Reported as:
Mean · Milliliters (mL)
Mean Volume of Contrast Media Used (mL) (mL)
Milliliters (mL)PlaceboVerapamil
Mean Volume of Contrast Media Used (mL) (mL)133.8 ± 71.9136.4 ± 78.3
SecondaryMean of the Dose Area Product (DAP)

The parameters collected for radiation exposure included the DAP

Time frame:
During the procedure (from sheath insertion to procedure completion)
Reported as:
Mean · Gy·cm2
Mean of the Dose Area Product (DAP)
Gy·cm2PlaceboVerapamil
Mean of the Dose Area Product (DAP)873.9 ± 732.3878.8 ± 736.7
SecondaryMean of the Fluoroscopy Time

The parameters collected for radiation exposure included the fluoroscopy time (in minutes)

Time frame:
During the procedure (from sheath insertion to procedure completion)
Reported as:
Mean · minute
Mean of the Fluoroscopy Time
minutePlaceboVerapamil
Mean of the Fluoroscopy Time7.9 ± 7.36.9 ± 5.8

Adverse events

Collected over From procedure initiation through hospital discharge (average 1 day). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/75 (0%)0/75 (0%)0/75 (0%)
Verapamil0/75 (0%)0/75 (0%)0/75 (0%)

Baseline characteristics

All randomized participants were included in the analysis

Age, Continuous
Age, Continuous(years)PlaceboVerapamilTotal
Mean58.1 ± 12.159.4 ± 11.158.8 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVerapamilTotal
Female232649
Male5249101
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PlaceboVerapamilTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)PlaceboVerapamilTotal
Turkey7575150
08

Study locations

1 site
  • VM Medicalpark
    Mersin, 33010, Turkey (Türkiye)
09

References and documents

Publications

  • Sural S, Dogen ME, Duzel B, Karaca O, Brilakis ES, Gorgulu S. The Role of Oral Verapamil in Preventing Radial Spasm During Transradial Angiography. Catheter Cardiovasc Interv. 2025 Aug;106(2):1247-1254. doi: 10.1002/ccd.31675. Epub 2025 Jun 8. PubMed 40485154 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Nov 2024, 4 months.

Results were first posted in Oct 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 7, 2024
StartActual
Jun 5, 2024
Primary completionActual
Nov 1, 2024
CompletionActual
Nov 15, 2024
Results first posted
Oct 10, 2025
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06447688
Lead sponsor
Mersin Medicalpark Hastanesi
Responsible party
Sefa Sural (MEDICAL DOKTOR( Principal investigator), Mersin Medicalpark Hastanesi) — Principal investigator
First posted
Jun 7, 2024
Start date
Jun 5, 2024
Primary completion
Nov 1, 2024
Completion
Nov 15, 2024
Results posted
Oct 10, 2025
Last update
Oct 10, 2025

Study contacts

Sefa Sural, MD
principal investigator · Istinye University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verapamil

Start the discussion